Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443274 · ClinicalTrials.gov registry record
Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
A clinical trial of Breast Implant, sponsored by Allergan.
- Active
- Registry status
- 56,460
- Enrollment target
- 1
- Study location
NCT00443274 is a study of Breast Implant that is active but no longer recruiting, run by Allergan. The registered enrollment target is 56,460 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00443274, a study of Breast Implant, is active but no longer recruiting, sponsored by Allergan.
- ACTIVE NOT RECRUITING
- Registry status
- 56,460 participants
- Enrollment target
- 1
- Study location
Study Summary
Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.
Conditions Studied
Interventions
- OTHER NBIR - US National Breast Implant Registry
- DEVICE 410 Arm
- DEVICE BIFs - Breast Implant Follow-Up Study
Study Locations (1)
Texas
- Southwest Plastic Surgery /ID# 240510 - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56,460 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443274
The ClinicalTrials.gov registry entry for NCT00443274 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 56,460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Implant appearing as the primary indexed condition, and to 3 interventions - of which NBIR - US National Breast Implant Registry is the first listed.
NCT00443274 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00443274 about?
NCT00443274 is a clinical study titled "Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms". Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.
What is the current status of trial NCT00443274?
This trial is currently active not recruiting. The enrollment target is 56,460 participants. The study started on 2006-11-01. Estimated completion is 2029-12-31.
What conditions does trial NCT00443274 study?
This clinical trial studies the following conditions: Breast Implant.
What interventions are being tested in trial NCT00443274?
The interventions under investigation include: NBIR - US National Breast Implant Registry (OTHER), 410 Arm (DEVICE), BIFs - Breast Implant Follow-Up Study (DEVICE).
Who is sponsoring clinical trial NCT00443274?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443274 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Implant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.